PPD (PPD) Stock Price, News & Analysis

Company Overview

PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.

Key Stats

• Today's Range: $47.28 to $47.28
• 50-Day Range: $47.10 to $47.41
• 52-Week Range: $31.54 to $47.41
• Volume: N/A
• Average Volume: 1.91 million shs
• Market Capitalization: $16.61 billion
• P/E Ratio: 47.28
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PPD Stock Analysis - Frequently Asked Questions

How were PPD's earnings last quarter?

PPD, Inc. (NASDAQ:PPD) posted its quarterly earnings data on Wednesday, October, 27th. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.05. The company's quarterly revenue was up 26.5% compared to the same quarter last year.

When did PPD IPO?

PPD (PPD) raised $1.5 billion in an initial public offering on Thursday, February 6th 2020. The company issued 60,000,000 shares at $24.00-$27.00 per share. Barclays, J.P. Morgan, Morgan Stanley, Goldman Sachs, BofA Securities, Credit Suisse, Jefferies, UBS Investment Bank, Citigroup, Deutsche Bank Securities, Evercore ISI, HSBC, Mizuho Securities, Baird and William Blair acted as the underwriters for the IPO and BofA Securities, Credit Suisse, Jefferies, UBS Investment Bank, Citigroup, Deutsche Bank Securities, Evercore ISI, HSBC, Mizuho Securities, Baird, William Blair and Drexel Hamilton were co-managers.

What other stocks do shareholders of PPD own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PPD investors own include Meta Platforms (META), Pfizer (PFE), NVIDIA (NVDA), Salesforce (CRM), Taiwan Semiconductor Manufacturing (TSM), Alibaba Group (BABA) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 10/27/2021
• Today: 9/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Commercial Physical Research
• Sub-Industry: N/A
• Current Symbol: NASDAQ:PPD
• CIK: 1793294
• Web: www.ppdi.com
• Phone: 910-251-0081
• Fax: N/A
• Employees: 26,000
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $1.00
• Trailing P/E Ratio: 47.28
• Forward P/E Ratio: 32.16
• P/E Growth: 2.11
• Net Income: $153.69 million
• Net Margins: 6.11%
• Pretax Margin: 7.31%
• Return on Equity: -89.48%
• Return on Assets: 7.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.23
• Quick Ratio: 1.23

Sales & Book Value

• Annual Sales: $4.68 billion
• Price / Sales: 3.55
• Cash Flow: $1.99 per share
• Price / Cash Flow: 23.71
• Book Value: ($1.21) per share
• Price / Book: -39.07

Miscellaneous

• Outstanding Shares: 351,395,000
• Free Float: 344,718,000
• Market Cap: $16.61 billion
• Optionable: Not Optionable
• Beta: 1.96